CABA

Cabaletta Bio (CABA)

About Cabaletta Bio (CABA)

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Details

Daily high

$2.87

Daily low

$2.74

Price at open

$2.83

52 Week High

$4.23

52 Week Low

$1.26

Market cap

461.4M

Dividend yield

0.00%

Volume

2.7M

Avg. volume

6.2M

P/E ratio

-1.43

Cabaletta Bio News